Biased Ligands. Better Drugs.

Poster - TRV130 FTIH study summary

First human dosing experience with TRV130, a G protein biased ligand at the mu opioid receptor. Presented at 2013 American Academy of Neurology meeting

David G. Soergel MD, Ruth Ann Subach PharmD, Jonathan D. Violin PhD, Dennis S. Yamashita PhD, Maxine Gowen PhD and Michael W. Lark PhD

View PDF

Copyright © Trevena, Inc.